Oncogene-driven hemostatic changes in cancer

Cancer Investigation

Volumn 27, Issue SUPPL. 1, 2009, Pages 28-35

  Rak, Janusz ^a,b   Yu, Joanne ^c   Milsom, Chloe ^b  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Cancer coagulopathy; Oncogenes; Tissue factor; Trousseau syndrome; Tumor initiating cells

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; THROMBOPLASTIN; UROKINASE; VASCULOTROPIN;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CANCER CELL; CANCER STEM CELL; CELL DIFFERENTIATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; INFLAMMATION; METASTASIS; NEOPLASM; ONCOGENE; PRIORITY JOURNAL; THROMBOSIS; TUMOR SUPPRESSOR GENE;

EID: 70349519221     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802656533     Document Type: Article

References (60)

1. Buller, H.R.; van Doormaal, F.F.; van Sluis, G.L.; Kamphuisen, P.W. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007, 5(Suppl. 1), 246-254.
2. Zwicker, J.I.; Furie, B.C.; Furie, B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007, 62, 126-136.
3. Falanga, A. Thrombophilia in cancer. Semin Thromb Hemost 2005, 31, 104-110.
4. Rickles, F.R. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006, 35, 103-110.
5. Trousseau, A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel -Dieu de Paris. The Sydenham Society 2nd. Paris, France. Ref Type: Serial (Book, Monograph), 1865, 654-712.
6. Varki, A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007, 110, 1723-1729.
7. Tesselaar, M.E.; Romijn, F.P.; van dL, I.; et al. Microparticleassociated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007, 5, 520-527.
8. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 438, 932-936.
9. Jain, R.K.; di, T.E.; Duda, D.G.; et al. Angiogenesis in brain tumors. Nat Rev Neurosci 2007, 8, 610-622.
10. Rickles, F.R.; Patierno, S.; Fernandez, P.M. Tissue factor, thrombin, and cancer. Chest 2003, 124, 58S-68S.
11. Petralia, G.A.; Lemoine, N.R.; Kakkar, A.K. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2005, 2, 356-363.
12. Rak, J.; Yu, J.L.; Luyendyk, J.; Mackman, N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006, 66, 10643-10646.
13. Blom, J.W.; Doggen, C.J.; Osanto, S.; Rosendaal, F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293, 715-722.
14. Svendsen, E.; Karwinski, B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989, 42, 805-809.
15. Levitan, N.; Dowlati, A.; Remick, S.C.; et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using medicare claims data. Medicine (Baltimore) 1999, 78, 285-291.
16. Mackman, N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol 2005, 25, 2273-2281.
17. Iversen, L.H.; Thorlacius-Ussing, O. Systemic coagulation reactivation in recurrence of colorectal cancer. Thromb Haemost 2003, 89, 726-734.
18. Kuenen, B.C.; Rosen, L.; Smit, E.F.; et al. Dose-finding and pharmacokinetic study of cisplatin, gGemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002, 20, 1657-1667.
19. Rickles, F.R.; Levine, M.N. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998, 28(Suppl. 3), 43-49.
20. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
21. Folkman, J.; Kalluri, R. Tumor angiogenesis. In: Cancer Medicine, D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, et al. (eds.). Hamilton, London: BC Decker Inc., 2003, 161-194.
22. Brown, L.F.; Guidi, A.J.; Schnitt, S.J.; et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999, 5, 1041-1056.
23. Kaplan, R.N.; Riba, R.D.; Zacharoulis, S.; et al. VEGFR1- positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005, 438, 820-827.
24. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
25. Bishop, J.M. Cancer: the rise of the genetic paradigm. Genes Dev 1995, 9, 1309-1315.
26. Rak, J.; Yu, J.L.; Klement, G.; Kerbel, R.S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000, 5, 24-33.
27. Rak, J.; Mitsuhashi, Y.; Bayko, L.; et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995, 55, 4575-4580.
28. Kerbel, R.S. Tumor angiogenesis. N Engl J Med 2008, 358, 2039-2049.
29. Ocak, I.; Baluk, P.; Barrett, T.; McDonald, D.M.; Choyke, P. The biologic basis of in vivo angiogenesis imaging. Front Biosci 2007, 12, 3601-3616.
30. Seaman, S.; Stevens, J.; Yang, M.Y.; et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007, 11, 539-554.
31. Dvorak, H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20, 4368-4380.
32. Mackman, N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004, 24, 1015-1022.
33. Mechtcheriakova, D.; Schabbauer, G.; Lucerna, M.; et al. Speci- ficity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001, 15, 230-242.
34. Contrino, J.; Hair, G.; Kreutzer, D.L.; Rickles, F.R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996, 2, 209-215.
35. Fidler, I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3, 453-458.
36. Dvorak, H.F.; Quay, S.C.; Orenstein, N.S.; et al. Tumor shedding and coagulation. Science 1981, 212, 923-924.
37. Yu, J.L.; May, L.; Lhotak, V.; et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005, 105, 1734-1741.
38. Rak, J.; Milsom, C.; Yu, J. Tissue factor in cancer. Curr Opin Hematol 2008, 15, 522-528.
39. Rak, J.; Klement, G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 2000, 19, 93-96.
40. Rastinejad, F.; Polverini, P.J.; Bouck, N. Regulation of the activity of a new inhibitor by angiogenesis by a cancer suppressor gene. Cell 1989, 56, 345-355.
41. Dameron, K.M.; Volpert, O.V.; Tainsky, M.A.; Bouck, N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994, 59, 483-489.
42. Bouck, N.; Stellmach, V.; Hsu, S.C. How tumors become angiogenic. Adv Cancer Res 1996, 69, 135-174.
43. Grugel, S.; Finkenzeller, G.; Weindel, K.; Barleon, B.; Marme, D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995, 270, 25915-25919.
44. Izumi, H.; Takahashi, C.; Oh, J.; Noda, M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett 2000, 481, 31-36.
45. Mazzieri, R.; Furlan, F.; D'Alessio, S.; et al. A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts. Oncogene 2007, 26, 725-732.
46. Zhao, Y.; Xiao, A.; Dipierro, C.G.; et al. H-Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathway. Glia 2008, 56, 917-924.
47. Pakneshan, P.; Szyf, M.; Rabbani, S.A. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells. Carcinogenesis 2005, 26, 557-564.
48. Scibetta, A.G.; Albanese, I.; Morris, J.; et al. Regulation of MUC1 expression in human mammary cell lines by the c-ErbB2 and ras signaling pathways. DNA Cell Biol 2001, 20, 265-274.
49. Jahner, D.; Hunter, T. The stimulation of quiescent rat fibroblasts by v-src and v-fps oncogenic protein-tyrosine kinases leads to the induction of a subset of immediate early genes. Oncogene 1991, 6, 1259-1268.
50. Yu, J.L.; May, L.; Klement, P.; Weitz, J.I.; Rak, J. Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004, 30, 21-30.
51. Al-Nedawi, K.; Meehan, B.; Micallef, J.; et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumor cells. Nat Cell Biol 2008, 10, 619-624.
52. Koizume, S.; Jin, M.S.; Miyagi, E.; et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006, 66, 9453-9460.
53. Schulze, E.B.; Hedley, B.D.; Goodale, D.; et al. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat 2008, 112, 243-254.
54. Tallman, M.S.; Lefebvre, P.; Baine, R.M.; et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004, 2, 1341-1350.
55. Boccaccio, C.; Sabatino, G.; Medico, E.; et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005, 434, 396-400.
56. Rong, Y.; Post, D.E.; Pieper, R.O.; et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005, 65, 1406-1413.
57. Ruf,W. Redundant signaling of tissue factor and thrombin in cancer progression? J Thromb Haemost 2007, 5, 1584-1587.
58. Pineo, G.F.; Brain, M.C.; Gallus, A.S.; et al. Tumors, mucus production, and hypercoagulability. Ann NY Acad Sci 1974, 230, 262-270.
59. Mackman, N.; Morrissey, J.H.; Fowler, B.; Edgington, T.S. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 1989, 28, 1755-1762.
60. Chen, J.; Bierhaus, A.; Schiekofer, S.; et al. Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001, 86, 334-345.